• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of new adjuvant using glycolipids from mycobacterium bovis BCG

Research Project

Project/Area Number 17K11124
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Urology
Research InstitutionInternational University of Health and Welfare

Principal Investigator

Miyazaki Jun  国際医療福祉大学, 医学部, 主任教授 (10550246)

Co-Investigator(Kenkyū-buntansha) 木村 友和  筑波大学, 医学医療系, 講師 (10633191)
西山 博之  筑波大学, 医学医療系, 教授 (20324642)
神鳥 周也  筑波大学, 医学医療系, 講師 (50707825)
矢野 郁也  大阪市立大学, 大学院医学研究科, 名誉教授 (60047008)
Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
KeywordsBCG / 癌免疫 / TDM / Mincle / 自然免疫 / ミコール酸 / 細胞壁 / 抗酸菌 / 細胞壁成分 / 腫瘍免疫 / 感染免疫 / 膀胱癌 / リポソーム / 癌免疫治療 / mycobacterium bovis BCG / 癌 / 免疫 / 尿路上皮癌 / 脂質
Outline of Final Research Achievements

Mycobacterium bovis BCG is given for non-muscle invasive bladder cancer. Its largest immunostimulatory cell wall component is the glycolipid trehalose-6 6'-dimycolate (TDM) which contains long chain fatty acid mycolic acid. TDM is recognized by the Mincle, a C-type lectin expressed on the surface of host immune cells. Therefore, we develop a new adjuvant formulation by using TDM into liposome and make TDM hydrophilic, TDM liposome propose a new cancer immunotherapy.

Academic Significance and Societal Importance of the Research Achievements

TDMのリポソームを最適化し、アジュバント活性を最大限有効になるよう調節することで、新しい癌免疫療法にむけたシーズとなる。TDMリポソームは、非生菌であることから、BCG菌のような全身播種性感染という重篤な副作用が起こらない。非生菌製剤であるため、生ワクチンのようなバイオハザードの管理も必要がなく、通常の薬剤と同様に管理、供給搬送が可能である。感染の可能性がないため、静脈内投与も含めたあらゆる投与方法が可能である。したがって、安全性と有効性の点で最も優れた治療薬として期待される。本研究は最も臨床的有用性の明らかな、安定した毒性の低い安価な癌免疫アジュバント製剤として期待される。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (7 results)

All 2019 2018 2017

All Journal Article (2 results) (of which Peer Reviewed: 2 results,  Open Access: 1 results) Presentation (3 results) (of which Int'l Joint Research: 2 results) Patent(Industrial Property Rights) (2 results) (of which Overseas: 1 results)

  • [Journal Article] Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Gu?rin induce antitumor immunity in a syngeneic murine bladder cancer model2019

    • Author(s)
      Yoshino Takayuki、Miyazaki Jun、Kojima Takahiro、Kandori Shuya、Shiga Masanobu、Kawahara Takashi、Kimura Tomokazu、Naka Takashi、Kiyohara Hideyasu、Watanabe Miyuki、Yamasaki Sho、Akaza Hideyuki、Yano Ikuya、Nishiyama Hiroyuki
    • Journal Title

      PLOS ONE

      Volume: 14 Issue: 1 Pages: 1-19

    • DOI

      10.1371/journal.pone.0209196

    • Related Report
      2019 Annual Research Report 2018 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Bacillus Calmette-Guerin strain differences as the basis for immunotherapies against bladder cancer2018

    • Author(s)
      Miyazaki Jun、Onozawa Mizuki、Takaoka Eiichiro、Yano Ikuya
    • Journal Title

      Int J Urol

      Volume: 印刷中 Issue: 5 Pages: 405-413

    • DOI

      10.1111/iju.13538

    • Related Report
      2017 Research-status Report
    • Peer Reviewed
  • [Presentation] Antitumor effect of cationic liposome incorporating keto-mycolic acid from Mycobacterium bovis bacillus Calmette-Guerin in mouse model.2018

    • Author(s)
      Takayuki Yoshino, Jun Miyazaki, Takahiro Kojim, Shuya Kandori, Hideyuki Akaza, Ikuya Yano, Hiroyuki Nishiyama
    • Organizer
      ASCO-GU
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] Antitumor effect of cationic liposome incorporating keto-mycolic acid from Mycobacterium bovis bacillus Calmette-Guérin in mouse model2018

    • Author(s)
      Takayuki Yoshino, Jun Miyazaki, Takahiro Kojima, Shuya Kandori, Hideyuki Akaza, Ikuya Yano, Hiroyuki Nishiyama
    • Organizer
      ASCO-GU
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research
  • [Presentation] Antitumor effect of liposome incorporating mycolic acid of Mycobacterium bovis bacillus Calmette-Guerin in mouse model2017

    • Author(s)
      Takayuki Yoshino, Jun Miyazaki, Hiroyuki Nishiyama, Hideyuki Akaza, Ikuya Yano
    • Organizer
      第74回日本癌学会学術総会
    • Related Report
      2017 Research-status Report
  • [Patent(Industrial Property Rights)] 非結核性抗酸菌感染症診断用キット、リポソーム2019

    • Inventor(s)
      西山博之、志賀正宣、渡邊真広、宮﨑淳、矢野郁也
    • Industrial Property Rights Holder
      西山博之、志賀正宣、渡邊真広、宮﨑淳、矢野郁也
    • Industrial Property Rights Type
      特許
    • Filing Date
      2019
    • Related Report
      2018 Research-status Report
  • [Patent(Industrial Property Rights)] リポソーム、抗癌剤及び癌治療用キット2018

    • Inventor(s)
      宮﨑淳、赤座英之、吉野喬之、西山博之
    • Industrial Property Rights Holder
      筑波大学、東京大学
    • Industrial Property Rights Type
      特許
    • Filing Date
      2018
    • Related Report
      2017 Research-status Report
    • Overseas

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi